These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 6391973)
1. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin. Johansen K Diabete Metab; 1984 Oct; 10(4):219-23. PubMed ID: 6391973 [TBL] [Abstract][Full Text] [Related]
2. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093 [TBL] [Abstract][Full Text] [Related]
4. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus. Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667 [TBL] [Abstract][Full Text] [Related]
5. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Hoffmann J; Spengler M Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831 [TBL] [Abstract][Full Text] [Related]
7. Clinical experience with acarbose: results of a Canadian multicentre study. Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019 [TBL] [Abstract][Full Text] [Related]
8. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Bayraktar M; Van Thiel DH; Adalar N Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572 [TBL] [Abstract][Full Text] [Related]
9. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Josse RG Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510 [TBL] [Abstract][Full Text] [Related]
13. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189 [TBL] [Abstract][Full Text] [Related]
14. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152 [TBL] [Abstract][Full Text] [Related]
15. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose. Scott RS; Knowles RL; Beaven DW Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178 [TBL] [Abstract][Full Text] [Related]
16. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887 [TBL] [Abstract][Full Text] [Related]
17. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287 [TBL] [Abstract][Full Text] [Related]
18. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508 [TBL] [Abstract][Full Text] [Related]
19. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Santeusanio F; Compagnucci P Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053 [TBL] [Abstract][Full Text] [Related]
20. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure]. Heuer LJ; Kaufmann HH Dtsch Z Verdau Stoffwechselkr; 1985; 45(2):52-8. PubMed ID: 3924553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]